InstalabLoading...
InstalabLoading...
The cells lining your colon get most of their energy from a single molecule made by your gut bacteria. When fiber-fermenting microbes thrive, your colon lining stays well-fueled, your gut barrier holds up, and signals travel from your gut to your immune system, brain, and metabolism in healthy ways. When those microbes are crowded out or starved of fiber, that fuel supply drops.
Measuring this fuel in your stool gives you a window into a part of your biology that no standard blood panel touches. The science is still maturing, so this is best used as one piece of a larger picture rather than a stand-alone verdict, but it can flag patterns worth investigating long before symptoms force the issue.
Butyrate is one of three main short-chain fatty acids (SCFAs, the small fat molecules made by fiber-fermenting gut bacteria, the others being acetate and propionate). Specific bacterial groups in your colon, including Faecalibacterium prausnitzii and Roseburia, produce most of it. Beyond fueling colon cells, it activates receptors on immune cells (called G-protein-coupled receptors, which act like docking stations on cell surfaces) and influences how genes are switched on and off through a process called HDAC inhibition (a way of changing gene activity without changing the DNA itself).
Stool butyrate reflects what your microbes are actually producing in your colon. It is not the same thing as butyrate in your blood, which is much lower because the colon and liver use most of it before it ever reaches general circulation. Stool measurements capture local microbial output. Blood measurements, where they exist, capture what spills past.
People with inflammatory bowel disease (IBD, the umbrella term for ulcerative colitis and Crohn's disease) tend to have lower butyrate and fewer butyrate-producing bacteria in their stool. A meta-analysis of multiple studies confirmed a quantitative drop in fecal short-chain fatty acids in IBD, especially during active flares. The biology is consistent: less fuel for the colon lining, weaker barrier, more inflammation.
If you have IBD, low stool butyrate is one signal among several that your microbial ecosystem is struggling. Trials of butyrate supplementation as an add-on therapy have shown mixed results, with one randomized study in newly diagnosed pediatric IBD finding no significant benefit and another reporting reduced disease activity and inflammation. A double-blind randomized trial in 36 adults with active ulcerative colitis found that sodium butyrate supplementation reduced disease severity and psychological symptoms compared with placebo.
An early case-control study compared fecal butyrate in 14 people with colorectal cancer and 14 healthy controls. A cutoff of less than 5.4 micrograms per milliliter (a measure of how much butyrate is in a small sample of stool) caught about 85 out of 100 cancer cases and correctly cleared 78 out of 100 healthy people, with an overall accuracy score (called AUC, where 1.0 is perfect and 0.5 is no better than a coin flip) of 0.84. This is a small, exploratory finding, not a replacement for colonoscopy or stool DNA testing, but it points to butyrate as one of several signals that may distinguish people with disease from those without.
An observational study of 388 adults found that people with more butyrate-producing gut bacteria tended to have better insulin sensitivity, suggesting that this microbial fuel system plays a role in how well your body handles blood sugar. A separate analysis using data from over 7,000 adults with diabetes found that higher dietary and circulating butyrate were each independently associated with better kidney function. These are correlations, not proof of cause, but they consistently link healthier butyrate biology with better metabolic outcomes.
Trials testing oral butyrate supplements have been less consistent. In a study of 19 lean and metabolic syndrome subjects, oral butyrate improved insulin sensitivity in lean men but not in those with metabolic syndrome. The body of human evidence so far suggests that supplementing butyrate directly is not a reliable shortcut to metabolic health for most people, even when low butyrate is part of the picture.
A prospective analysis of 136,910 UK Biobank adults examined the combination of dietary pattern and a genetic estimate of how much butyrate a person's microbes likely produce. People with both high dietary quality and high genetically predicted butyrate had about 18% lower risk of developing multiple cardiometabolic diseases over follow-up (hazard ratio 0.82, 95% confidence interval 0.69 to 0.96).
In a separate cohort of 260 Chinese adults on dialysis, those in the highest third of serum butyrate had roughly 63% lower cardiovascular mortality over 91 months than those in the lowest third (hazard ratio 0.368, 95% confidence interval 0.187 to 0.724), even after adjusting for standard risk factors. Note that this evidence comes from serum butyrate, a different measurement than stool butyrate, so the link between higher stool levels and these specific outcomes has not been directly established.
An observational study of 104 adults found that fecal butyric acid alone could distinguish people with mild fatty liver disease from those without it, with an accuracy score of 0.83 (where 1.0 is perfect). A randomized trial of oral butyrate in 181 people with metabolic dysfunction-associated steatotic liver disease (MASLD, the new name for fatty liver tied to insulin resistance and metabolic problems) found benefit in some subgroups but no significant overall improvement in liver fat. As with other conditions, low stool butyrate appears to be a marker of the underlying microbial state, not necessarily something that can be fixed by swallowing more of it.
One large cross-sectional study of 441 adults found that people with higher fecal short-chain fatty acid levels (including butyrate) actually had more obesity, higher blood pressure, and worse cardiometabolic risk markers, alongside signs of gut microbiome imbalance. This sounds like it contradicts everything else, but it does not. Higher stool levels can reflect either strong microbial production with normal absorption, or normal production with poor absorption and an imbalanced gut. A high or low number on its own does not tell you which scenario you are in. This is part of why butyrate is best read alongside other gut markers and clinical context, not as a single good number versus bad number.
There are no consensus clinical cutpoints for stool butyrate. The only published, structured reference range comes from a study of 455 healthy pregnant women in Spain, which measured serum (not stool) butyrate by mass spectrometry and reported a first-trimester range of 0.32 to 1.67 micromolar (a unit for very small concentrations in blood). That range is specific to pregnancy and a different specimen type than stool, so it does not translate to a target for the test you are ordering.
Your lab's report will give you a value with the lab's own reference interval based on its specific assay. Treat that interval as orientation, not a clinical target, and focus on changes within the same lab over time.
Stool butyrate can vary substantially depending on what you ate in the last few days, which microbes happen to be active, and how completely the sample was collected. A single number is rarely enough to make decisions on. The more useful question is: what direction is it moving in over months, and does it move when you change something deliberately?
A reasonable approach is to get a baseline, then retest in 3 to 6 months if you make meaningful changes to fiber intake, fiber type, or your broader gut therapy, and at least annually thereafter if you are actively tracking gut health. Always compare results from the same lab using the same assay, since methods differ enough between labs that absolute numbers are not directly comparable.
If your stool butyrate comes back low, the most useful next step is to look at it alongside other markers from a fuller stool workup: the abundance of butyrate-producing bacteria like Faecalibacterium prausnitzii and Roseburia, levels of other short-chain fatty acids (acetate and propionate), and inflammatory markers like calprotectin and secretory IgA (an antibody your gut lining makes to defend against microbes). A pattern of low butyrate plus low butyrate producers plus elevated calprotectin is far more informative than butyrate alone, and would justify a conversation with a gastroenterologist or functional medicine clinician about gut-directed interventions.
If your level is high, do not assume that means everything is fine. Pair the result with symptoms (gut, metabolic, weight), other gut markers, and your overall clinical picture before drawing conclusions. The most useful thing you can do with any single butyrate result is set up the next one and watch the trajectory.
Evidence-backed interventions that affect your Butyrate level
Butyrate is best interpreted alongside these tests.